Pharmacology of therapeutic botulinum toxin preparations

Disability and Rehabilitation

Volumn 29, Issue 23, 2007, Pages 1761-1768

  Dressler, Dirk ^a   Benecke, Reiner ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Adverse effects; Antibodies; Botulinum toxin; Mode of action; Pharmacology; Therapy

Indexed keywords

AMINOGLYCOSIDE; ANTIBODY; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN ANTIBODY; BOTULINUM TOXIN B; EXCIPIENT; SNARE PROTEIN; UNCLASSIFIED DRUG;

ACCOMMODATION DISORDER; ANTIGENICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTONOMIC NEUROPATHY; BIOLOGICAL ACTIVITY; BRACHIAL PLEXUS NEUROPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CORNEA DISEASE; DEVELOPMENTAL DISORDER; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG LABELING; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG PURIFICATION; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; GENITAL SYSTEM DISEASE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MOTOR DYSFUNCTION; NEUROMODULATION; NONHUMAN; NOSE IRRITATION; PARESIS; PRIORITY JOURNAL; RISK FACTOR; SHELF LIFE; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; HUMANS; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS;

EID: 36549049448     PISSN: 09638288     EISSN: 14645165     Source Type: Journal    
DOI: 10.1080/09638280701568296     Document Type: Article

References (55)

1. Kerner, J. Vergiftung durch verdorbene Würste. Tübinger Blätter f Naturwissensch u Arzneykunde, 3, pp. 1-25.
2. Kerner, J. Neue Beobachtungen über die in Würthemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuβ geräucherter Würste, GF Osiander, Tübingen
3. Kerner, J. Das Fettgift und die Fettsäure und ihre Wirkungen auf den thierischen Organismus. Ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes, Cotta-Verlag, Stuttgart und Tübingen
4. Schantz, E. J. (1994) Historical perspective. Therapy with Botulinum toxin, pp. XXIII-XXVI. Marcel Dekker, Inc., New York, Basel, Hong Kong
5. Scott, A. B., Rosenbaum, A. and Collins, C. C. (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol, 12, pp. 924-927.
6. Scott, A. B. (1994) Foreword. Therapy with Botulinum toxin, pp. VII-IX. Marcel Dekker, Inc., New York, Basel, Hong Kong
7. Scott, A. B. (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus, 17, pp. 21-25.
8. Dressler, D., Benecke, R. and Conrad, B. (1989) Botulinum-Toxin in der Therapie kraniozervikaler Dystonien. Nervenarzt, 60, pp. 386-394.
9. Dressler, D. (2000) Botulinum Toxin Therapy, Thieme Verlag, Stuttgart, New York
10. Pellizzari, R., Rossetto, O., Schiavo, G. and Montecucco, C. (1999) Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci, 354, pp. 259-268.
11. Schiavo, G., Santucci, A., Dasgupta, B. R., Mehta, P. P., Jontes, J., Benfenati, F., Wilson, M. C. and Montecucco, C. (1993) Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett, 335, pp. 99-103.
12. Binz, T., Blasi, J., Yamasaki, S., Baumeister, A., Link, E., Sudhof, T. C., Jahn, R. and Niemann, H. (1994) Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem, 269, pp. 1617-1620.
13. Foran, P., Lawrence, G. W., Shone, C. C., Foster, K. A. and Dolly, J. O. (1996) Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: Correlation with its blockade of catecholamine release. Biochemistry, 35, pp. 2630-2636.
14. Schiavo, G., Benfenati, F., Poulain, B., Rossetto, O., de Laureto, P Polverino, Das-Gupta, B. R. and Montecucco, C. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature, 359, pp. 832-835.
15. Yamasaki, S., Baumeister, A., Binz, T., Blasi, J., Link, E., Cornille, F., Roques, B., Fykse, E. M., Sudhof, T. C. and Jahn, R. (1994) Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem, 269, pp. 12764-12772.
16. Duchen, L. W. (1971) An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci, 14, pp. 47-60.
17. Duchen, L. W. (1971) Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin. J Neurol Sci, 14, pp. 61-74.
18. de Paiva, A., Meunier, F. A., Molgo, J., Aoki, K. R. and Dolly, J. O. (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA, 96, pp. 3200-3205.
19. Brin, M. F., Dressler, D. and Aoki, R. (2004) Pharmacology of botulinum toxin therapy. Dystonia: Etiology, clinical features, and treatment, pp. 93-112. Lippincott Williams & Wilkins, Philadelphia
20. Dressler, D. and Rothwell, J. C. (2000) Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol, 43, pp. 13-16.
21. Dressler, D., Rothwell, J. C. and Bigalke, H. (2000) The sternocleidomastoid test: An in vivo assay to investigate botulinum toxin antibody formation in man. J Neurol, 247, pp. 630-632.
22. Filippi, G. M., Errico, P., Santarelli, R., Bagolini, B. and Manni, E. (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol, 113, pp. 400-404.
23. Dressler, D., Eckert, J., Kukowski, B. and Meyer, B. U. (1993) Somatosensorisch Evozierte Potentiale bei Schreibkrampf: Normalisierung pathologischer Befunde unter Botulinum Toxin Therapie. Z EEG EMG, 24, p. 191.
24. Rosales, R. L., Arimura, K., Takenaga, S. and Osame, M. (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve, 19, pp. 488-496.
25. Kaji, R., Kohara, N., Katayama, M., Kubori, T., Mezaki, T., Shibasaki, H. and Kimura, J. (1995) Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle Nerve, 18, pp. 234-235.
26. Kaji, R., Rothwell, J. C., Katayama, M., Ikeda, T., Kubori, T., Kohara, N., Mezaki, T., Shibasaki, H. and Kimura, J. (1995) Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neuro, 138, pp. 155-162.
27. Wiegand, H., Erdmann, G. and Wellhoner, H. H. (1976) 125I-labelled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol, 292, pp. 161-165.
28. Takamizawa, K., Iwamori, M., Kozaki, S., Sakaguchi, G., Tanaka, R., Takayama, H. and Nagai, Y. (1986) TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett, 201, pp. 229-232.
29. Sanders, D. B., Massey, E. W. and Buckley, E. G. (1986) Botulinum toxin for blepharospasm: Single-fibre EMG studies. Neurology, 36, pp. 545-547.
30. Lange, D. J., Brin, M. F., Warner, C. L., Fahn, S. and Lovelace, R. E. (1987) Distant effects of local injection of botulinum toxin. Muscle Nerve, 10, pp. 552-555.
31. Olney, R. K., Aminoff, M. J., Gelb, D. J. and Lowenstein, D. H. (1988) Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology, 38, pp. 1780-1783.
32. Girlanda, P., Vita, G., Nicolosi, C., Milone, S. and Messina, C. (1992) Botulinum toxin therapy: Distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry, 55, pp. 844-845.
33. Dressler, D. and Benecke, R. (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol, 49, pp. 34-38.
34. Ishikawa, H., Mitsui, Y., Yoshitomi, T., Mashimo, K., Aoki, S., Mukuno, K. and Shimizu, K. (2000) Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol, 44, pp. 106-109.
35. Purkiss, J., Welch, M., Doward, S. and Foster, K. (2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms. Biochem Pharmacol, 59, pp. 1403-1406.
36. Welch, M. J., Purkiss, J. R. and Foster, K. A. (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon, 38, pp. 245-258.
37. Cui, M., You, S., Khanijou, S. and Aoki, R. (2002) Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing. Arch Pharmacol, 365, p. R17.
38. McMahon, H., Foran, P. and Dolly, J. (1992) Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: Clues to the locus of action. J Biol Chem, 267, pp. 21338-21343.
39. Morris, J., Jobling, P. and Gibbins, I. (2001) Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol, 281, pp. 2124-2132.
40. Shone, C. C. and Melling, J. (1992) Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem, 207, pp. 1009-1016.
41. Dressler, D., Saberi, F Adib and Benecke, R. (2002) Botulinum toxin type B for treatment of axillary hyperhidrosis. J Neurol, 249, pp. 1729-1732.
42. Benecke, R., Jost, W. H., Kanovsky, P., Ruzicka, E., Comes, G. and Grafe, S. (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology, 64, pp. 1949-1951.
43. Dressler, D. and Saberi, F Adib (2006) Safety aspects of high dose Xeomin® therapy. J Neurol, 253, p. II/141.
44. Dressler, D. and Dirnberger, G. (2000) Botulinum toxin therapy: Risk factors for therapy failure. Mov Disord, 15, p. 51.
45. Dressler, D. Immunological aspects of botulinum toxin therapy. Neurology
46. Jankovic, J., Vuong, K. D. and Ahsan, J. (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology, 60, pp. 1186-1188.
47. Pickett, A., Panjwani, N. and O'Keeffe, R. S. Potency of Type A Botulinum toxin preparations in clinical use. 40th Annual Meeting of the Interagency Botulism Research Coordinating Committee (IBRCC) Atlanta, USA
48. Settler, P. (2000) The biochemistry of botulinum toxin type B. Neurology, 55, p. S22.
49. Dressler, D. and Benecke, R. (2006) Xeomin® eine neue therapeutische Botulinum Toxin Typ A-Präparation. Akt Neurol, 33, pp. 138-141.
50. Dressler, D. (2000) Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol, 247, pp. 809-810.
51. Dressler, D. (2004) New formulation of BOTOX®: Complete antibody-induced therapy failure in hemifacial spasm. J Neurol, 251, p. 360.
52. Probst, T. E., Heise, H., Heise, P., Benecke, R. and Dressler, D. (2002) Rare immunologic side effects of botulinum toxin therapy: Brachial plexus neuropathy and dermatomyositis. Mov Disord, 17, p. S49.
53. Erbguth, F., Claus, D., Engelhardt, A. and Dressler, D. (1993) Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiat, 56, pp. 1235-1236.
54. Dressler, D. (2002) Dysport produces intrinsically more swallowing problems than Botox: Unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry, 73, p. 604.
55. Dressler, D. and Eleopra, R. (2006) Clinical use of non-A botulinum toxins: Botulinum toxin type B. Neurotox Res, 9, pp. 121-125.